Annual Report

Overview

The report presents Xlife Sciences' 2024 portfolio and financial performance, including the BiTAC platform launch, Synimmune acquisition, and announced VERAXA NASDAQ listing. It reports consolidated revenue of CHF 834,877 and 17 employees at year-end. Sustainability coverage describes a GRI-based ESG report, Board and ESG Committee monitoring, Scope 1-3 environmental tracking, 44% female representation across Xlife and project companies, and support for the Kenya Biogas Programme.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2024
Period: 1 January 2024 – 31 December 2024
Language: English
Pages
File size

Reporting standards, commitments and assurance details are available with a free account.

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP
Other

Ratings

GRI level

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services